Expression of nuclear factor-kappaB family proteins in hepatocellular carcinomas

Oncology

Volumn 72, Issue 1-2, 2007, Pages 97-104

  O'Neil, Bert H ^a,b,d   Bůžková, Petra ^b,c   Farrah, Hillary ^b   Kashatus, David ^b   Sanoff, Hanna ^a   Goldberg, Richard M ^a,b   Baldwin, Albert S ^b   Funkhouser, William K ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c IL   (United States)

^d UNIVERSITY OF NORTH CAROLINA HOSPITALS   (United States)

Author keywords

Bcl 3; Hdm2; Nuclear factor B

Indexed keywords

I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 3;

ARTICLE; CELL NUCLEUS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER CELL CARCINOMA; MALE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; TUMOR CELL; WESTERN BLOTTING;

CARCINOMA, HEPATOCELLULAR; CELL NUCLEUS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; I-KAPPA B KINASE; IMMUNOHISTOCHEMISTRY; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; NF-KAPPA B P50 SUBUNIT; NF-KAPPA B P52 SUBUNIT; PROTO-ONCOGENE PROTEINS; TRANSCRIPTION FACTORS;

EID: 37049004740     PISSN: 00302414     EISSN: None     Source Type: Journal    
DOI: 10.1159/000111116     Document Type: Article

References (36)

1. Davila JA, et al: Hepatitis C infection and the increasing incidence of hepatocellular carcinoma: a population-based study. Gastroenterology 2004;127:1372-1380.
2. Cavin LG, et al: Regulation of α-fetoprotein by nuclear factor-κB protects hepatocytes from tumor necrosis factor-α cytotoxicity during fetal liver development and hepatic oncogenesis. Cancer Res 2004;64:7030-7038.
3. Chan CF, et al: Evaluation of nuclear factor-κB, urokinase-type plasminogen activator, and HBx and their clinicopathological significance in hepatocellular carcinoma. Clin Cancer Res 2004;10:4140-4149.
4. Chiao PJ, et al: Role of Rel/NF-κB transcription factors in apoptosis of human hepatocellular carcinoma cells. Cancer 2002;95:1696-1705.
5. Tai DI, Tsai SL, Chang YH, Huang SN, Chen TC, Chang KSS, Liaw YF: Constitutive activation of nuclear factor-κB in hepatocellular carcinoma. Cancer 2000;89:2274-2281.
6. Factor V, et al: Roles of Akt/PKB and IKK complex in constitutive induction of NF-κB in hepatocellular carcinomas of transforming growth factor-α/c-myc transgenic mice. Hepatology 2001;34:32-41.
7. Girard S, et al: Hepatitis C virus NS5A-regulated gene expression and signaling revealed via microarray and comparative promoter analyses. Hepatology 2004;40:708-718.
8. Liu P, et al: Activation of NF-κB, AP-1 and STAT transcription factors is a frequent and early event in human hepatocellular carcinomas. J Hepatol 2002;37:63-71.
9. Tai D-I, et al: Activation of nuclear factor κB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology 2000;31:656-664.
10. Wang J, Huang Q, Chen M: The role of NF-κB in hepatocellular carcinoma cell. Chin Med J (Engl) 2003;116:747-752.
11. Waris G, et al: Hepatitis C virus NS5A and subgenomic replicon activate NF-κB via tyrosine phosphorylation of IκBα and its degradation by calpain protease. J Biol Chem 2003;278:40778-40787.
12. Baldwin AS: Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107:241-246.
13. Kerr LD, et al: The proto-oncogene bcl-3 encodes an IκB protein. Genes Dev 1992;6:2352-2363.
14. Beg AA, Baldwin AS Jr: The IκB proteins: multifunctional regulators of Rel/NF-κB transcription factors. Genes Dev 1993;7:2064-2070.
15. Khoshnan A, et al: The NF-κB cascade is important in Bcl-xL expression and for the antiapoptotic effects of the CD28 receptor in primary human CD4+ lymphocytes. J Immunol 2000;165:1743-1754.
16. Wang CY, et al: NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281:1680-1683.
17. Xiao G, et al: Alternative pathways of NF-κB activation: a double-edged sword in health and disease. Cytokine Growth Factor Rev 2006;17:281-293.
18. Bours V, et al: The oncoprotein Bcl-3 directly transactivates through κB motifs via association with DNA-binding p50B homodimers. Cell 1993;72:729-739.
19. Fujita T, et al: The candidate proto-oncogene bcl-3 encodes a transcriptional coactivator that activates through NF-κB p50 homodimers. Genes Dev 1993;7:1354-1363.
20. Thornburg NJ, Pathmanathan R, Raab-Traub N: Activation of nuclear factor-κB p50 homodimer/Bcl-3 complexes in nasopharyngeal carcinoma. Cancer Res 2003;63:8293-8301.
21. Pallares J, et al: Abnormalities in the NF-κB family and related proteins in endometrial carcinoma. J Pathol 2004;204:569-577.
22. Ong ST, et al: Lymphadenopathy, splenomegaly, and altered immunoglobulin production in BCL3 transgenic mice. Oncogene 1998;16:2333-2343.
23. Crossen PE: Cytogenetic and molecular changes in chronic B-cell leukemia. Cancer Genet Cytogenet 1989;43:143-150.
24. Ohno H, Takimoto G, McKeithan TW: The candidate proto-oncogene bcl-3 is related to genes implicated in cell lineage determination and cell cycle control. Cell 1990;60:991-997.
25. Tanaka S, et al: Reciprocal t(14;19)(q32.3; q13.1) in a patient with B-cell lymphoma. Cancer Genet Cytogenet 1990;49:219-224.
26. Bours V, et al: Cloning of a mitogen-inducible gene encoding a κB DNA-binding protein with homology to the Rel oncogene and to cell-cycle motifs. Nature 1990;348:76-80.
27. van Krieken JH, et al: Chromosomal translocation t(14;19) as indicated by bcl-3 rearrangement is a rare phenomenon in non-Hodgkin's lymphoma and chronic lymphocytic leukemia: a molecular genetic analysis of 176 cases. Leukemia 1990;4:811-812.
28. Cogswell PC, et al: Selective activation of NF-κB subunits in human breast cancer: potential roles for NF-κB2/p52 and for Bcl-3. Oncogene 2000;19:1123-1131.
29. Westerheide SD, et al: The putative oncoprotein Bcl-3 induces cyclin D1 to stimulate G(1) transition. Mol Cell Biol 2001;21:8428-8436.
30. Kashatus D, Cogswell PC, Baldwin AS: Expression of the Bcl-3 proto-oncogene suppresses p53 activation. Genes Dev, in press.
31. Dechend R, et al: The Bcl-3 oncoprotein acts as a bridging factor between NF-κB/Rel and nuclear co-regulators. Oncogene 1999;18:3316-3323.
32. Watanabe J, et al: Bcl-xL overexpression in human hepatocellular carcinoma. Int J Oncol 2002;21:515-519.
33. Watanabe J, et al: Prognostic significance of Bcl-xL in human hepatocellular carcinoma. Surgery 2004;135:604-612.
34. Takehara T, et al: Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 2001;34:55-61.
35. Sakurai H, et al: IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999;274:30353-30356.
36. Park SG, et al: Up-regulation of cyclin D1 by HBx is mediated by NF-κB2/BCL3 complex through κB site of cyclin D1 promoter. J Biol Chem 2006;281:31770-31777.